Orion Portfolio Solutions LLC Trims Stock Position in Immunocore Holdings plc (NASDAQ:IMCR)

Orion Portfolio Solutions LLC decreased its position in Immunocore Holdings plc (NASDAQ:IMCR) by 9.9% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 20,692 shares of the company’s stock after selling 2,282 shares during the period. Orion Portfolio Solutions LLC’s holdings in Immunocore were worth $644,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of IMCR. Wellington Management Group LLP lifted its holdings in shares of Immunocore by 10.5% in the 3rd quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company’s stock worth $219,430,000 after buying an additional 668,382 shares during the period. FMR LLC raised its holdings in shares of Immunocore by 0.5% in the third quarter. FMR LLC now owns 4,836,040 shares of the company’s stock valued at $150,546,000 after acquiring an additional 23,436 shares in the last quarter. Primecap Management Co. CA lifted its stake in Immunocore by 26.7% in the third quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock worth $76,954,000 after acquiring an additional 520,950 shares during the period. Bellevue Group AG grew its holdings in Immunocore by 4.4% during the 3rd quarter. Bellevue Group AG now owns 1,205,464 shares of the company’s stock worth $37,526,000 after acquiring an additional 50,810 shares in the last quarter. Finally, Armistice Capital LLC increased its position in Immunocore by 495.1% during the 2nd quarter. Armistice Capital LLC now owns 976,000 shares of the company’s stock valued at $33,077,000 after purchasing an additional 812,000 shares during the period. Institutional investors own 84.50% of the company’s stock.

Immunocore Stock Up 1.5 %

NASDAQ:IMCR opened at $29.33 on Tuesday. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. Immunocore Holdings plc has a twelve month low of $28.17 and a twelve month high of $76.98. The company has a market cap of $1.47 billion, a PE ratio of -30.87 and a beta of 0.73. The company’s 50 day moving average is $32.25 and its two-hundred day moving average is $35.09.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.50. The firm had revenue of $80.25 million for the quarter, compared to analyst estimates of $78.94 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The business’s quarterly revenue was up 23.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.59) earnings per share. Analysts anticipate that Immunocore Holdings plc will post -0.94 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. UBS Group started coverage on shares of Immunocore in a research note on Thursday, October 24th. They set a “sell” rating and a $24.00 price objective on the stock. Morgan Stanley reiterated an “equal weight” rating and issued a $35.00 price target (down from $74.00) on shares of Immunocore in a report on Friday. Mizuho cut Immunocore from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $72.00 to $38.00 in a research note on Monday, November 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunocore in a research note on Monday, September 9th. Finally, Guggenheim lowered shares of Immunocore from a “buy” rating to a “neutral” rating in a research report on Monday, October 7th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $65.64.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.